The European Journal of Contraception and Reproductive Health Care Impact Factor & Information

Publisher: European Society of Contraception, Informa Healthcare

Journal description

The Official Journal of the European Society of Contraception, The European Journal of Contraception and Reproductive Health Care publishes original peer-reviewed research papers as well as review papers and other appropriate educational material. The Editors welcome submissions from members of the European Society of Contraception and also from non-members anywhere in the world.

Current impact factor: 1.84

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 1.835
2012 Impact Factor 1.808
2011 Impact Factor 1.456
2010 Impact Factor 1.616
2009 Impact Factor 0.973
2008 Impact Factor 0.824
2007 Impact Factor 0.862
2006 Impact Factor 0.467
2005 Impact Factor 0.721
2004 Impact Factor 0.48
2003 Impact Factor 0.571

Impact factor over time

Impact factor
Year

Additional details

5-year impact 1.64
Cited half-life 5.00
Immediacy index 0.17
Eigenfactor 0.00
Article influence 0.46
Website European Journal of Contraception and Reproductive Health Care, The website
Other titles European journal of contraception & reproductive health care (Online), European journal of contraception and reproductive health care
ISSN 1473-0782
OCLC 49885918
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • On a non-profit server
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Regulatory agencies in the United States (US) and Europe differ in requirements for defining pregnancies after the last dose of oral contraceptive, sometimes resulting in discrepant Pearl Indices (PIs) for the same product despite identical clinical data. This brief report highlights one such example, a 91-day extended-regimen combined oral contraceptive (COC). Methods The US- and European-based PI methodologies were compared for a 91-day extended-regimen COC consisting of 84 days of active levonorgestrel/EE 150 μg/30 μg tablets, followed by seven days of EE 10 μg tablets in place of placebo. Conclusions At the times of approval of the 91-day extended-regimen COC in the US and Europe, the requirements for defining 'on-treatment' pregnancies differed (14-day vs. 2-day rule, respectively). This difference resulted in a higher PI in the US- vs. European-based calculation (1.34 and 0.76, respectively). The differences in the PI should not be interpreted as the extended-regimen COC being less effective in preventing pregnancy in the US compared with Europe.
    The European Journal of Contraception and Reproductive Health Care 06/2015; DOI:10.3109/13625187.2015.1059416
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Our study aimed to explore the association between the use of effective contraceptive methods and access to different contraceptive services, as well as to describe accessibility-related obstacles when using contraceptive services and satisfaction with those services. Methods From a population-based cross-sectional study carried out in 2004 (response rate 53.8%), the data of 16- to 24-year-old women requiring contraception (N = 868) were analysed. Factors associated with the use of effective contraceptive methods and, specifically, hormonal methods, were explored using multiple logistic regression analysis. Results Effective contraception was used by 75.1% of the respondents. The use of effective contraceptive methods was associated with school-based sexuality education (adjusted prevalence odds ratio 2.69; 95% confidence interval 1.32 - 5.50), visiting a youth-friendly clinic (YFC) (1.82; 1.03-3.23) or a private gynaecologist (2.08; 1.11-3.92). The use of hormonal methods was additionally associated with being a native Estonian speaker and visiting a family doctor. More than half of the respondents reported some obstacle in accessing contraceptive services. The highest satisfaction ratings were given to YFCs. Conclusions Steps to promote the use of services that are youth-friendly and associated with better uptake of effective contraceptive methods are needed among all 16- to 24-year-old women.
    The European Journal of Contraception and Reproductive Health Care 06/2015; DOI:10.3109/13625187.2015.1057699
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives The aims of the study were to examine in Portuguese schools the facilitating factors at micro- and exosystem levels generally associated with more effective implementation of sexuality education (SE). Methods A representative sample of principals/lead teachers from 296 Portuguese schools completed a questionnaire about SE at school that included items related to factors at micro- and exosystem levels. Bivariate and multivariate logistic regression analyses were performed to examine factors associated with the development of an SE project. Results The majority of schools (96%) implemented some form of SE. Specifically, 79% of schools had developed an SE project. The odds that a school had designed an SE project increased significantly when the school did not implement extracurricular activities only (odds ratio [OR] 7.9), when it had an SE team (OR 7.2) and when it had established partnerships (OR 4.5). Bivariate and multivariate logistic regression models for each factor and each level revealed that other variables were associated with the development of a project, such as the perceived support offered by the regional education department. Conclusions The results highlight the importance of variables at micro- and exosystem levels as facilitating factors, and reinforce the ecological approach as being well suited for SE/health education in schools. The findings have implications for policy-makers as well as for practice.
    The European Journal of Contraception and Reproductive Health Care 06/2015; DOI:10.3109/13625187.2015.1057809
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and objectives The literature concerning the history of condoms is replete with errors. The paper Youssef published in 1993 is in our opinion the best. We update and expand the information. Methods To mention only established facts, we accessed primary sources, which are identified in the article. Findings The origin of the term 'condom' remains an enigma. Plausible hypotheses are that it is derived from either (i) the Latin 'condĕre' (to sheathe) or the corresponding noun 'condus' (receptacle); or (ii) the Venetian variant 'gondon' of the Italian word 'guantone' (glove). The earliest identified mention of a similar barrier method is in the legend of Minos and Pasiphae written (in the 2nd century AD) by Antoninus Liberalis. A penile sheath, made from animal gallbladder, was advocated in the 10th century by the Persian physician Al-Akhawayni. The earliest surviving condoms made of animal membranes date back to between 1642 and 1646. Such 'skin' condoms became increasingly popular for prevention of venereal disease, but as early as the 18th century their value as contraceptives was appreciated. Rubber condoms were available from 1855; since 1930, they are made of latex. We mention, in parallel, the most striking changes over time in sexual mores and behaviours, and illustrate these by referring to colourful figures such as, among others, Boswell, Mrs Philips, Casanova, Marguerite Gourdan, and Richard Carlile. Conclusion Papers related to this topic often contain errors, which we identify. Condoms over time evolved from animal gut receptacles to reliable contraceptives protecting also against certain sexually transmitted infections, including HIV.
    The European Journal of Contraception and Reproductive Health Care 06/2015; DOI:10.3109/13625187.2015.1050716
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Since its introduction 50 years ago, the contraceptive pill has continuously evolved to decrease the risk of venous thromboembolism (VTE) associated with its use. An increased risk of VTE still remains, however. Other concerns, such as effects on lipid and carbohydrate metabolism, have also been reported. In this study we compared two reference combined oral contraceptives (COCs) containing ethinylestradiol (EE)/levonorgestrel (LNG) and EE/drospirenone (DRSP) with COCs containing estradiol (E2) (estradiol valerate [E2V]/dienogest [DNG] and E2/nomegestrol acetate [NOMAC]). They were evaluated according to their influence on recognised haemostatic and metabolic markers. Methods A literature search of the MEDLINE/PubMed database was conducted for head-to-head studies. EE/LNG was chosen as the comparator pill. Results The haemostatic impact of E2 pills and EE/LNG has been extensively compared, in contrast to that of EE/DRSP and EE/LNG. Changes in haemostatic and metabolic marker levels between EE/LNG and E2V/DNG were generally not statistically significant. E2/NOMAC showed statistically significantly favourable results on haemostatic markers and had a neutral effect on carbohydrate and lipid metabolism when compared with EE/LNG. Conclusion E2/NOMAC exhibits less haemostatic and metabolic impact than EE/LNG and other COCs, suggesting that it may be a promising candidate to reduce residual VTE risk associated with COC use. Confirmation from a well-powered prospective clinical trial is, however, needed.
    The European Journal of Contraception and Reproductive Health Care 05/2015; DOI:10.3109/13625187.2015.1050091
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives As over 125 million women worldwide have undergone female genital mutilation (FGM), 170,000 of whom are estimated to live in the UK alone, obstetricians and gynaecologists need to be aware of the grades and consequences of this devastating condition. Women with type III FGM, even when they are unable to have penetrative intercourse, can conceive, and obstetricians should be aware of this to ensure optimal care of these patients. To determine the most appropriate surgical approach, deinfibulation in pregnancy should follow some basic principles which take into account the psychological needs of women as well as the extent of scarring. Cases We present two cases of women who had never engaged in penetrative intercourse and therefore presented with no knowledge that they were pregnant. They underwent antenatal deinfibulation and subsequent management based on individual request. Conclusions Management in pregnancy can pose particular problems and should be individualised. In all childbearing women with FGM, even where intercourse has not been possible, pregnancy should be considered. Clinicians should be aware of the types of FGM and management should be undertaken by a designated clinician with appropriate expertise. Pregnant women who have undergone FGM should be examined to identify the requirement for antenatal surgical correction.
    The European Journal of Contraception and Reproductive Health Care 05/2015; DOI:10.3109/13625187.2015.1044083
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives The study aimed to explore the factors facilitating and inhibiting female condom use among female university students in South Africa. Methods This qualitative study drew on 15 individual, in-depth interviews with female university students in Durban, South Africa. Results The results of the study highlight several factors that facilitate and inhibit female condom use. Protection from sexually transmitted infections (including HIV/AIDS) and prevention of pregnancy facilitated use of the device among female students. In addition, students expressed positive attitudes towards the female condom and preferred it to hormonal contraceptives because it offered them dual protection. Absence of side effects and greater power and autonomy to initiate safer sex were other factors that facilitated use. Inadequate availability, partner objection, stigma, insertion difficulties and lack of awareness served as significant barriers to consistent female condom use. Conclusions Although the female condom can protect female students from infections and pregnancy, there are several barriers to its use. Interventions should aim to increase availability of the female condom, and male involvement should be increased to facilitate consistent use of the method.
    The European Journal of Contraception and Reproductive Health Care 04/2015; DOI:10.3109/13625187.2015.1036415
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Men play a well-recognised role in reproductive health care. They are pertinent to the achievement of female reproductive health. This study assessed male involvement in reproductive health issues in Nigeria and identified relevant factors. Methods This was a cross-sectional study of 1530 married men aged 25 to 45 years selected by a multi-stage sampling procedure. Bivariate and logistic regression analyses were performed, with male involvement in reproductive health care as the dependent variable. Results The mean age of the respondents was 38.64 (± 5 SD) years. Although 65.9% of the respondents discussed reproductive health issues with their wife, only 39.6% accompanied them during visits to clinics. Less than one-third (30.9%) of the respondents were involved in reproductive health care. Male involvement in reproductive health care is predicted by having completed at least secondary education (OR 4.337; p = 0.007), having one or no living child (OR 2.002; p = 0.001), and approval of family planning (OR 2.637; p = 0.000). Conclusions Male involvement in reproductive health care is predicted by level of education, number of living children and approval of family planning. There is a need to focus on the identified factors in order to strengthen and increase male participation in reproductive health care.
    The European Journal of Contraception and Reproductive Health Care 04/2015; DOI:10.3109/13625187.2015.1036856
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To determine women's (patients') experiences of intrauterine device (IUD) insertion under our current practice and the extent to which these agreed with the observations of the health professionals (providers) who had performed the IUD insertion procedures. Method Questionnaires were used to collect information on women's experiences of the IUD insertion procedure from both patients and providers in a sexual and reproductive health service. Results Overall response rates were high (77%, 284 responses in total). Seventy-three percent of patients were nulliparous and over half nulligravid. The providers predominantly used local anaesthesia for IUD insertions (93%). Most patients reported being anxious before their procedure (86%). Patients mainly described the overall experience of their IUD insertion procedure as being associated with 'minimal discomfort/nothing' (42%) or 'uncomfortable' (41%). 'Minimal discomfort/nothing' (56%) and 'uncomfortable' (33%) were the main observations of providers. When responses of patients and their providers were compared, agreement was slight for reported pain levels (k = 0.167 CI [0.13-0.24]). Patients' reported pain levels were significantly higher than those reported to have been observed by their providers (p < 0.001). Conclusion Patients' and providers' responses suggested that the IUD insertion procedure under our current practice appeared acceptable to most patients. However, providers were not usually accurate in their observations and tended to underestimate the degree of pain experienced by their patients during IUD insertion procedures.
    The European Journal of Contraception and Reproductive Health Care 04/2015; DOI:10.3109/13625187.2015.1031885
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of the study was to estimate the burden and direct medical costs of unintended pregnancy to the public payer in Spain. Methods An economic model evaluating the costs and outcomes of contraceptive use over a 1-year period was constructed for women in Spain aged 15 to 44 years at risk of pregnancy. Model inputs were derived from published literature and national survey data. Outcomes evaluated included: (i) the annual number of unintended pregnancy events and their cost; (ii) the proportion of unintended pregnancy events and their cost due to non-adherence; and (iii) the use and cost of contraceptive methods in Spain. Results Of the total number of pregnancies, 35% are estimated to be unintended and are associated with a direct cost burden of €292.8 million per year. Most unintended pregnancies (26%) occur in women aged 30 to 34 years, whilst 69% of the total cost burden is estimated to be attributable to poor adherence to contraceptive methods. Conclusions The cost associated with unintended pregnancy is high. The major proportion of the burden is estimated to be attributable to imperfect adherence and is likely avoidable. Shifts in patterns of contraceptive use, combined with measures to improve adherence, could have a substantial and positive impact on this burden.
    The European Journal of Contraception and Reproductive Health Care 04/2015; DOI:10.3109/13625187.2015.1028617
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The study aimed to investigate the effect of concomitant use of atorvastatin or rosuvastatin on the pharmacokinetic and pharmacodynamic profile of centchroman, a non-steroidal female oral contraceptive. Methods A rat model was used to predict pharmacokinetic drug–drug interactions between centchroman and atorvastatin or rosuvastatin. A dried blood spot sampling technique followed by liquid chromatography–tandem mass spectrometry detection was employed for analysis of the pharmacokinetic interaction study samples. Sperm-positive female rats were investigated for postcoital contraceptive activity of centchroman with or without coadministration of atorvastatin or rosuvastatin. Results Coadministration of atorvastatin or rosuvastatin may increase the systemic availability of centchroman in blood, but it does not affect the pharmacodynamic profile of centchroman. Conclusion Atorvastatin or rosuvastatin may be prescribed with centchroman without compromising the contraceptive efficacy of centchroman.
    The European Journal of Contraception and Reproductive Health Care 03/2015; 20(3):231–235. DOI:10.3109/13625187.2015.1017756
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives To study the anti-fertility effect of a DNA vaccine using Bin1b as the target antigen in male mice. Methods A novel recombinant eukaryotic vector containing a fusion gene sequence of mouse Bin1b in tandem with three copies of C3d fragment (C3d3) was used to construct pSG.SS.C3d3.YL.Bin1b. The correct expression of the Bin1b-C3d3 protein was confirmed in transfected HEK293 cells by indirect immunofluorescence and western blot analysis. The fertility of immunised mice was determined by a mating experiment and sperm motility test. Anti-Bin1b antibody titres in sera were examined by ELISA assays. Binding activity of C3d3 fragment of the fusion protein was verified in C3d receptor-expressing Raji cells and flow cytometric analysis. Results Immunisation of pSG.SS.C3d3.YL.Bin1b recombinant DNA vaccine significantly decreased sperm motility and compromised fertility in male mice. ELISA results showed that the titres of anti-Bin1b IgG in sera of immunised mice increased markedly with the immunisation process. Further, the anti-fertility effect of pSG.SS.C3d3.YL.Bin1b was significantly better than that of pSG.SS.YL.Bin1b DNA vaccine and generated higher titres of anti-Bin1b antibody. Conclusions Our results show that recombinant DNA vaccine targeting Bin1b can markedly reduce fertility in male mice, providing an alternative approach for birth control.
    The European Journal of Contraception and Reproductive Health Care 03/2015; DOI:10.3109/13625187.2015.1021771